Biotechnology News and Research

RSS

Aushon plans global launch of new multiplex protein biomarker platform

Aushon announced its plans today for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance.

21 May 2012

BIOCRATES Life Sciences to introduce AbsoluteIDQ p180 and p150 research kits

Austrian BIOCRATES Life Sciences AG, prime developer of state-of-the-art metabolite biomarker panels, is about to launch new editions of two of its well-established research kit products -AbsoluteIDQ p180 and p150.

21 May 2012

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Active Biotech and Ipsen today announced that recruitment to the global, pivotal, randomized, double-blind, placebo-controlled phase III study of tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC) has reached an inclusion of 600 patients, half of the planned accrual.

21 May 2012

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference.

21 May 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.

19 May 2012

Final results from C3BS-CQR-1 Phase II trial on heart failure

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

19 May 2012

Survey: Healthcare marketers should target insured Hispanic women ages 25-35

A new national survey commissioned by Cultur Health shows healthcare marketers should target insured Hispanic women ages 25-35. These young Latinas, representing a rapidly growing Hispanic demographic, are key healthcare gatekeepers – managing their own health needs and frequently those of their families, parents, grandparents and other relatives as well.

19 May 2012

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting.

19 May 2012

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer.

19 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

BIT Companies support Rays of Hope organization to help South African children

BIT Companies, developer/manufacturer of in-vitro diagnostic, clinical and hematology instrumentation, has announced its role as a supporter of Rays of Hope, a non-profit organization in South Africa which offers sustainable aid to underprivileged children in a small village on the outskirts of Johannesburg, South Africa.

19 May 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

18 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012

ScreenCell, Affymetrix partner to distribute CTC platform

Affymetrix, Inc. and ScreenCell, a privately-held company, today announced the signing of a worldwide distribution agreement for ScreenCell's isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

18 May 2012

Avraham initiates ladostigil Phase 2 trial in MCI

Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment.

18 May 2012

Researchers identify 57 SNPs associated with autism

By focusing on the identification of common genetic variants, researchers have identified 57 single nucleotide polymorphisms (SNPs) that predict-with a high degree of certainty--the risk that siblings of children with Autism Spectrum Disorder (ASD) will also develop the condition. The findings were presented at the International Meeting for Autism Research.

18 May 2012

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

Agfa HealthCare opens state-of-the-art, worldwide R&D facility for clinical imaging IT solutions development

Facility is a center of excellence for the design of innovative solutions that will bring further revolutionary developments for radiology, pathology and healthcare delivery as a whole to image-enable the Electronic Health Record (EHR)

17 May 2012

Cardiac ischemia plays an important role in adenovector gene transfection in mammalian hearts

Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA.

17 May 2012

Mary Ann Liebert releases BioResearch Open Access journal

The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.

17 May 2012